Faster-Acting Insulins
Program Overview
Biochemical and Physiological Actions of Insulin
Insulin and Glucose Profiles: Healthy Subjects
Exogenous vs Endogenous Insulin
Exogenous vs Endogenous Insulin (cont)
Therapeutic Objectives in Diabetes Management
Factors Affecting Insulin Absorption
Insulin Uptake From SC Tissue: Advantages of Rapid-Acting Insulins
Meta-Analysis: Better Postprandial BG Control With Insulin Aspart vs RHI
Insulin Aspart Significantly Reduced the Rate of Severe Nocturnal Hypoglycemia in T1DM
CGM Analysis
Need for Faster-Acting Insulins
PPG as a Glycemic Target
Agents for Control of PPG
Advantages of Rapid-Acting Analogues vs RHI
Rapid-Acting Insulin Analogues and PPG Control: Current Challenges
Guidelines for the Management of Postprandial Hyperglycemia: T1DM
ADA Recommendations: Combination Injectable Therapy in T2DM
AACE Algorithm for Intensifying Insulin
Faster Aspart: A New Formulation of Insulin Aspart
Onset of Exposure of Faster Aspart: Pooled Analysis of 6 Studies in Patients With T1DM
Early Exposure of Faster Aspart: Early Exposure of Faster Aspart:* Pooled Analysis of 6 Studies in Patients With T1DM
Faster Aspart: Onset and "Offset" of Exposure*
Onset® 3: Study Design
Onset® 3: Mean HbA1c Over Time
Onset® 3: 8-Point SMPG Profile at Week 18
Onset® 2*: Mean Change in HbA1c Over Time
Onset® 2: PPG Increment (Meal Test) at Week 26
Ultra-Rapid Insulin Lispro U100 in Patients With T2DM
PK Differences: Ultra-Rapid Insulin Lispro U100 vs Insulin Lispro in T2DM
PD Differences: Ultra-Rapid Insulin Lispro U100 vs Insulin Lispro in T2DM
Onset® 1: Study Design
Onset® 1: Mean HbA1c Change From Baseline
Onset® 1: PPG Increment at Week 26
Onset® 1: Safety
Ultra-Rapid Formulation of Lispro U100 in Patients With T1DM
PK/PD Differences: Ultra-Rapid Insulin Lispro U100 vs Insulin Lispro in T1DM
Onset, Offset, and Overall Exposure of Faster Aspart vs Insulin Aspart in CSII
Better PPG Control in CSII With Faster Aspart*
Role of Faster Aspart in the Management of Patients With Diabetes
Concluding Remarks